GlassScriptPhysician profile
Suraj Pratap
NPI 1114201704
$1,014.11
in general payments reported to CMS, 2019-2025
20 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.43 · 2021: $115 · 2022: $29.03 · 2023: $109 · 2024: $544 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $786.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $301.37 | 2019-2024 | |
| Kedrion Biopharma, INC. | $98.49 | 2024 | Gammaked, Kedrab, Koate |
| Takeda Pharmaceuticals U.S.A., INC. | $83.82 | 2021-2025 | Advate, Vpriv |
| Chiesi USA, INC. | $71.61 | 2024-2025 | Elfabrio |
| Biomarin Pharmaceutical INC. | $59.85 | 2024 | Roctavian |
| Glaxosmithkline, LLC. | $39.33 | 2021 | |
| Jazz Pharmaceuticals INC. | $39.09 | 2024 | |
| Octapharma USA, INC. | $33.39 | 2024 | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) |
| Sanofi Pasteur INC. | $29.03 | 2022 | |
| Sobi, INC | $28.96 | 2024 | |
| Biogen, INC. | $28.22 | 2025 | Spinraza |
| Merck Sharp & Dohme LLC | $27.67 | 2023 | Gardasil 9, Vaxelis, M-M-R II |
| Genentech USA, INC. | $27.32 | 2023 | Hemlibra |
| Servier Pharmaceuticals LLC | $24.71 | 2024 | |
| Genetix Biotherapeutics INC | $23.77 | 2025 | Lyfgenia |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $23.67 | 2024 | |
| Genzyme Corporation | $23.33 | 2024 | |
| Rare Disease Therapeutics, INC. | $19.18 | 2024 | Purixan |
| Pharming Healthcare, INC. | $16.07 | 2025 | Ruconest |
| Hema Biologics, LLC | $15.23 | 2024 | Sevenfact |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suraj Pratap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.